AIM-HI Accelerator Fund Portfolio Company Receives Virginia Catalyst Funding
ROCKVILLE, MD – A portfolio start-up company of the AIM-HI Accelerator Fund has been awarded $700,000 from Virginia Catalyst to commercialize its lead cancer drug candidate. Richmond-based InterLeukin Combinatorial Therapies (ILCT) is developing unique engineered therapeutic interleukins (a type of…
